文献速递其他结缔组织病

系统性硬化症最早阶段以血清炎症蛋白升高为特征

Earliest Phase of Systemic Sclerosis Typified by Increased Levels of Inflammatory Proteins in the Serum.
PubMed 文献 · Arthritis Rheumatol · 2017-10-30

研究对21例EaSSc、15例非纤维化SSc和11例健康对照进行88重免疫检测,筛选出16个分子在扩大样本中验证。结果显示CXCL10、CXCL11、TNFRII和CHI3L1在EaSSc和非纤维化SSc中显著升高,且高浓度CXCL10和TNFRII与更快进展相关。

要点

  • EaSSc和非纤维化SSc患者血清CXCL10、CXCL11、TNFRII和CHI3L1显著高于健康对照。
  • 高浓度CXCL10和TNFRII与从EaSSc或非纤维化SSc向更差阶段更快进展相关。
  • 非纤维化SSc已存在与疾病演变相关的分子改变,为疾病拦截提供新途径。

核心结论

  • 临床前/早期SSc和已确立但非纤维化的SSc患者存在明确的分子改变,这些改变与更快的疾病演变速率相关。

研究设计与样本

  • 发现队列纳入21例EaSSc(符合LeRoy和Medsger标准)、15例非纤维化SSc(符合ACR/EULAR 2013分类标准且无皮肤或肺纤维化)和11例健康对照,进行88重免疫检测。
  • 验证队列纳入47例EaSSc、48例非纤维化SSc、43例健康对照,以及51例lcSSc和35例dcSSc患者。

主要发现

  • 探索性分析以P值阈值0.1筛选出16个分子进入验证分析。
  • 验证结果显示CXCL10、CXCL11、TNFRII和CHI3L1在EaSSc和非纤维化SSc患者中较健康对照显著升高。
  • 高浓度CXCL10和TNFRII患者的疾病特征为从EaSSc和非纤维化SSc向更差疾病阶段进展的速率更快。

关键数值与推荐

  • EaSSc符合LeRoy和Medsger标准;非纤维化SSc符合ACR/EULAR 2013分类标准且无皮肤或肺纤维化。
  • 探索性分析P值阈值设为0.1;验证分析以家族错误率0.05检验预测SSc进展的价值。

临床怎么用

  • 对EaSSc和非纤维化SSc患者可检测血清CXCL10、CXCL11、TNFRII和CHI3L1水平以识别分子改变。
  • CXCL10和TNFRII高浓度提示疾病进展更快,可能有助于风险分层和疾病拦截策略的探索。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Patients with definite systemic sclerosis (SSc) who lack fibrotic features can be stratified into an intermediate stage of disease severity between preclinical/early SSc (EaSSc) and fibrotic subsets (limited cutaneous SSc [lcSSc] and diffuse cutaneous SSc [dcSSc]). The aim of the present study was to molecularly characterize nonfibrotic SSc and EaSSc on the basis of a broad panel of serum markers of inflammation and tissue damage, in order to increase the knowledge of the pathophysiologic mechanisms underlying SSc progression before the development of fibrosis. METHODS: An 88-plex immunoassay was performed in serum samples from a discovery cohort composed of 21 patients with EaSSc (meeting the LeRoy and Medsger criteria), 15 with nonfibrotic SSc (meeting the American College of Rheumatology/European League Against Rheumatism 2013 classification criteria, without skin or lung fibrosis), and 11 healthy controls. Analyte concentrations that were consistently significantly different at the exploratory P value threshold of 0.1 were selected for replication analysis in a larger group composed of 47 patients with EaSSc, 48 with nonfibrotic SSc, and 43 healthy controls, as well as 51 patients with lcSSc and 35 with dcSSc. The value of the replicated molecules in predicting SSc progression (at a family-wise error rate of 0.05) was tested. RESULTS: Based on the results of the explorative analysis, 16 molecules were selected for testing in the replication set. The results showed that CXCL10, CXCL11, tumor necrosis factor receptor type II (TNFRII), and chitinase 3-like protein 1 levels were significantly increased in patients with EaSSc and those with nonfibrotic SSc as compared to healthy controls. The disease in patients with high concentrations of CXCL10 and TNFRII was also characterized by a faster rate of progression from EaSSc and from nonfibrotic SSc to worse disease stages. CONCLUSION: SSc patients with preclinical/early SSc and those with established, yet nonfibrotic, disease exhibit clear molecular alterations that are associated with faster rates of disease evolution. These data open novel avenues for disease interception in SSc.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Cossu M, van Bon L, Preti C, et al. Earliest Phase of Systemic Sclerosis Typified by Increased Levels of Inflammatory Proteins in the Serum. Arthritis Rheumatol. 2017. PMID: 28859262. doi:10.1002/art.40243

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。